Related references
Note: Only part of the references are listed.An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia
W. Stock et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci
Chiara Campo et al.
NEUROCHEMICAL RESEARCH (2017)
Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy
Maria Sereno et al.
BMC CANCER (2017)
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)
M. Kanai et al.
ANNALS OF ONCOLOGY (2016)
A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma
Florence Magrangeas et al.
CLINICAL CANCER RESEARCH (2016)
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Daniel L. Hertz et al.
CLINICAL CANCER RESEARCH (2016)
Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials
Dawn L. Hershman et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population
Angela Gutierrez-Camino et al.
PHARMACOGENETICS AND GENOMICS (2016)
Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia
Elixabet Lopez-Lopez et al.
PHARMACOGENOMICS (2016)
Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)
Ganesh K. Boora et al.
CANCER MEDICINE (2016)
Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer
Lise Eckhoff et al.
ACTA ONCOLOGICA (2015)
Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors
M. A. Dimopoulos et al.
ANNALS OF ONCOLOGY (2015)
Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Bryan P. Schneider et al.
CLINICAL CANCER RESEARCH (2015)
Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia
Barthelemy Diouf et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance)
Ganesh K. Boora et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis
Salvatore Terrazzino et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2015)
Pharmacogenomics in the clinic
Mary V. Relling et al.
NATURE (2015)
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study
Paola Tacchetti et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Sequencing of Charcot-Marie-Tooth Disease Genes in a Toxic Polyneuropathy
Andreas S. Beutler et al.
ANNALS OF NEUROLOGY (2014)
Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study
A. Custodio et al.
ANNALS OF ONCOLOGY (2014)
Bortezomib-induced peripheral neurotoxicity: an update
Andreas A. Argyriou et al.
ARCHIVES OF TOXICOLOGY (2014)
Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes
Susanna B. Park et al.
BMC CANCER (2014)
Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel
Jean E. Abraham et al.
CLINICAL CANCER RESEARCH (2014)
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy
Soo-Youn Lee et al.
EUROPEAN JOURNAL OF CANCER (2014)
Neurotoxicity induced by antineoplastic proteasome inhibitors
Albert Ale et al.
NEUROTOXICOLOGY (2014)
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
Marta Seretny et al.
PAIN (2014)
Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia
Francesco Ceppi et al.
PHARMACOGENOMICS (2014)
Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer
Jatinder Kaur Lamba et al.
PHARMACOGENOMICS (2014)
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients
Annamaria Ruzzo et al.
SCIENTIFIC REPORTS (2014)
Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature
Andreas A. Argyriou et al.
CANCER MANAGEMENT AND RESEARCH (2014)
The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia
Rosalyn P Sims
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2014)
Voltage-Gated Sodium Channel Polymorphisms Play a Pivotal Role in the Development of Oxaliplatin-Induced Peripheral Neurotoxicity Results From a Prospective Multicenter Study
Andreas A. Argyriou et al.
CANCER (2013)
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer
Kyung-Hun Lee et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
Heather E. Wheeler et al.
CLINICAL CANCER RESEARCH (2013)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
Tomohiro Nishina et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy
Luis J. Leandro-Garcia et al.
JOURNAL OF MEDICAL GENETICS (2013)
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen
E. Cecchin et al.
PHARMACOGENOMICS JOURNAL (2013)
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy A Prospective Clinical Study
Markus Joerger et al.
CANCER (2012)
Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients
Hong-Hee Won et al.
CANCER (2012)
A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101
R. Michael Baldwin et al.
CLINICAL CANCER RESEARCH (2012)
Pharmacogenomics Knowledge for Personalized Medicine
M. Whirl-Carrillo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Andreas A. Argyriou et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Adverse interactions between antifungal azoles and vincristine: review and analysis of cases
Brad Moriyama et al.
MYCOSES (2012)
Factors Exacerbating Peripheral Neuropathy Induced by Paclitaxel Plus Carboplatin in Non-small Cell Lung Cancer
Kazuyoshi Kawakami et al.
ONCOLOGY RESEARCH (2012)
Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity
Romain Guilhaumou et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients
Sophie L. Corthals et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma
David C. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach
Andrew S. Moore et al.
JOURNAL OF PAEDIATRICS AND CHILD HEALTH (2011)
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
Bertrand Coiffier et al.
LANCET ONCOLOGY (2011)
Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide
Maria Teresa Cibeira et al.
LEUKEMIA RESEARCH (2011)
Regulation of CCL2 Expression by an Upstream TALE Homeodomain Protein-Binding Site That Synergizes with the Site Created by the A-2578G SNP
Stephen H. Page et al.
PLOS ONE (2011)
Increased Risk of Vincristine Neurotoxicity Associated With Low CYP3A5 Expression Genotype in Children With Acute Lymphoblastic Leukemia
Akinbode Egbelakin et al.
PEDIATRIC BLOOD & CANCER (2011)
Genetic variation associated with bortezomib-induced peripheral neuropathy
Reyna Favis et al.
PHARMACOGENETICS AND GENOMICS (2011)
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
Annemiek Broyl et al.
LANCET ONCOLOGY (2010)
Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival
Brian Van Ness et al.
BMC MEDICINE (2008)
Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy
A. A. Argyriou et al.
EUROPEAN JOURNAL OF CANCER CARE (2007)
Bortezomib in the treatment of cancer
Aldo M. Roccaro et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2006)
Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?
AA Argyriou et al.
SUPPORTIVE CARE IN CANCER (2006)
Microtubules as a target for anticancer drugs
MA Jordan et al.
NATURE REVIEWS CANCER (2004)
Share Paper
